Daniel Winetsky1,2,3, Daniel Burack4, Pantelis Antoniou1, Bill Garcia5, Peter Gordon1,2, Matthew Scherer1,2. 1. Comprehensive Health Program, New York Presbyterian Hospital, New York, USA. 2. Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA. 3. HIV Center for Clinical and Behavioral Studies at Columbia University and New York State Psychiatric Institute, New York, USA. 4. Department of Medicine, Columbia University Irving Medical Center, New York, USA. 5. Washington Heights Corner Project, New York, USA.
Abstract
BACKGROUND: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) is highly effective. However, people who inject drugs face significant barriers to DAA access. METHODS: We describe a program that colocates HCV management within a syringe service program in New York City. We performed a retrospective chart review of all patients with confirmed HCV viremia. RESULTS: From 2015 to 2018, 102 patients with viremia completed intake. Fifty-eight patients started DAAs. Nine patients discontinued treatment or were lost to follow-up before completion; 1 is continuing DAA treatment. Of 48 patients who completed therapy, sustained virologic response (SVR) was achieved in 43 (89.6%). Age and established mental health treatment at intake were associated with SVR. Regular cocaine use was negatively associated with SVR in univariate analysis, but this association was not significant after adjustment for age. Of 30 patients completing DAA therapy with active illicit opioid use at intake, 14 (46.4%) engaged in opioid use disorder (OUD) treatment during therapy, and 9 remained in OUD treatment after completion of DAA treatment. CONCLUSIONS: Loss to follow-up is a challenge for people who inject drugs, but among those who completed treatment, SVR was achieved at a high rate. Mental health treatment may facilitate HCV cure. Conversely, HCV therapy may facilitate engagement in OUD treatment and other services.
BACKGROUND: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) is highly effective. However, people who inject drugs face significant barriers to DAA access. METHODS: We describe a program that colocates HCV management within a syringe service program in New York City. We performed a retrospective chart review of all patients with confirmed HCV viremia. RESULTS: From 2015 to 2018, 102 patients with viremia completed intake. Fifty-eight patients started DAAs. Nine patients discontinued treatment or were lost to follow-up before completion; 1 is continuing DAA treatment. Of 48 patients who completed therapy, sustained virologic response (SVR) was achieved in 43 (89.6%). Age and established mental health treatment at intake were associated with SVR. Regular cocaine use was negatively associated with SVR in univariate analysis, but this association was not significant after adjustment for age. Of 30 patients completing DAA therapy with active illicit opioid use at intake, 14 (46.4%) engaged in opioid use disorder (OUD) treatment during therapy, and 9 remained in OUD treatment after completion of DAA treatment. CONCLUSIONS: Loss to follow-up is a challenge for people who inject drugs, but among those who completed treatment, SVR was achieved at a high rate. Mental health treatment may facilitate HCV cure. Conversely, HCV therapy may facilitate engagement in OUD treatment and other services.
Authors: Emma Day; Tina Broder; Julie Bruneau; Sally Cruse; Melisa Dickie; Suzanne Fish; Celine Grillon; Niklas Luhmann; Kate Mason; Elizabeth McLean; Stacey Trooskin; Carla Treloar; Jason Grebely Journal: Int J Drug Policy Date: 2019-02-08
Authors: Meghan D Morris; Ali Mirzazadeh; Jennifer L Evans; Alya Briceno; Phillip Coffin; Judith A Hahn; Kimberly A Page Journal: Drug Alcohol Depend Date: 2019-02-27 Impact factor: 4.492
Authors: Don C Des Jarlais; K Arasteh; J Feelemyer; C McKnight; David M Barnes; David C Perlman; A Uuskula; H L F Cooper; Susan Tross Journal: Drug Alcohol Depend Date: 2018-09-12 Impact factor: 4.492
Authors: Heather Bradley; H Irene Hall; Richard J Wolitski; Michelle M Van Handel; Amy E Stone; Michael LaFlam; Jacek Skarbinski; Darrel H Higa; Joseph Prejean; Emma L Frazier; Roshni Patel; Ping Huang; Qian An; Ruiguang Song; Tian Tang; Linda A Valleroy Journal: MMWR Morb Mortal Wkly Rep Date: 2014-11-28 Impact factor: 17.586
Authors: Cornelia Metzig; Julian Surey; Marie Francis; Jim Conneely; Ibrahim Abubakar; Peter J White Journal: Sci Rep Date: 2017-05-12 Impact factor: 4.379
Authors: Becky L Genberg; Rachel E Gicquelais; Jacquie Astemborski; Jennifer Knight; Megan Buresh; Jing Sun; Danielle German; David L Thomas; Gregory D Kirk; Shruti H Mehta Journal: Drug Alcohol Depend Date: 2021-10-30 Impact factor: 4.852
Authors: Maria A Corcorran; Judith I Tsui; John D Scott; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2021-01-11 Impact factor: 4.492
Authors: Kevin F Kamis; David L Wyles; Matthew S Minturn; Tracy Scott; Dean McEwen; Hermione Hurley; Scott J Prendergast; Jessie Gunter; Sarah E Rowan Journal: Health Justice Date: 2022-08-10
Authors: Kevin F Kamis; David L Wyles; Matthew S Minturn; Tracy Scott; Dean McEwen; Hermione Hurley; Scott J Prendergast; Sarah E Rowan Journal: Open Forum Infect Dis Date: 2021-12-16 Impact factor: 3.835